1.1. Executive Summary: Global Oral GLP-1 Drugs Market

2.1. Research Objective

2.2. Product Overview

2.3. Market Segmentation

2.4. Qualitative Research
2.4.1. Primary & Secondary Sources

2.5. Quantitative Research
2.5.1. Primary & Secondary Sources

2.6. Breakdown of Primary Research Respondents, By Region

2.7. Assumption for Study

2.8. Market Size Estimation

2.9. Data Triangulation

3.1. Industry Value Chain Analysis
3.1.1. API & Drug Substance Suppliers (Peptides, Small Molecules, Absorption Enhancers)
3.1.2. Oral GLP-1 Drug Developers & Manufacturers
3.1.3. Formulation & Oral Delivery Technology Providers
3.1.4. Distribution Channels (Hospital, Retail, Online Pharmacies)
3.1.5. Healthcare Providers (Hospitals, Clinics, Specialty Centers) & Patients

3.2. Industry Outlook
3.2.1. Overview of the Global Incretin / Metabolic Therapy & Anti-Obesity Industry
3.2.2. Pipeline Race: Oral Semaglutide, Orforglipron & Next-Gen Co-Agonists
3.2.3. Access, Pricing & Reimbursement Dynamics vs. Injectable GLP-1s

3.3. PESTLE Analysis

3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitutes
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition

3.5. Market Growth and Outlook
3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
3.5.2. Price Trend Analysis, By Drug Type

4.1. Competition Dashboard
4.1.1. Market Concentration Rate
4.1.2. Company Market Share Analysis (Value %), 2025
4.1.3. Competitor Mapping & Benchmarking

5.1. Market Dynamics and Trends
5.1.1. Growth Drivers
5.1.2. Restraints
5.1.3. Opportunity
5.1.4. Key Trends

5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
5.2.1. By Drug Type
5.2.1.1. Key Insights
5.2.1.1.1. Oral Peptide GLP-1 Agonists
5.2.1.1.2. Small-Molecule Non-Peptide GLP-1 Agonists
5.2.2. By Molecule
5.2.2.1. Key Insights
5.2.2.1.1. Semaglutide (Oral)
5.2.2.1.2. Orforglipron
5.2.2.1.3. Danuglipron
5.2.2.1.4. Other Emerging Candidates
5.2.3. By Indication
5.2.3.1. Key Insights
5.2.3.1.1. Type 2 Diabetes
5.2.3.1.2. Obesity / Weight Management
5.2.3.1.3. Cardiometabolic / NASH
5.2.3.1.4. Others
5.2.4. By Patient Population
5.2.4.1. Key Insights
5.2.4.1.1. Diabetic
5.2.4.1.2. Obese / Overweight
5.2.4.1.3. Cardiovascular-Risk
5.2.5. By Distribution Channel
5.2.5.1. Key Insights
5.2.5.1.1. Hospital & Specialty Pharmacies
5.2.5.1.2. Retail Pharmacies
5.2.5.1.3. Online Pharmacies
5.2.6. By End User
5.2.6.1. Key Insights
5.2.6.1.1. Hospitals & Clinics
5.2.6.1.2. Homecare
5.2.6.1.3. Specialty Centers
5.2.7. By Region
5.2.7.1. Key Insights
5.2.7.1.1. North America
5.2.7.1.1.1. The U.S.
5.2.7.1.1.2. Canada
5.2.7.1.1.3. Mexico
5.2.7.1.2. Europe
5.2.7.1.2.1. Western Europe
5.2.7.1.2.1.1. The UK
5.2.7.1.2.1.2. Germany
5.2.7.1.2.1.3. France
5.2.7.1.2.1.4. Italy
5.2.7.1.2.1.5. Spain
5.2.7.1.2.1.6. Rest of Western Europe
5.2.7.1.2.2. Eastern Europe
5.2.7.1.2.2.1. Poland
5.2.7.1.2.2.2. Russia
5.2.7.1.2.2.3. Rest of Eastern Europe
5.2.7.1.3. Asia Pacific
5.2.7.1.3.1. China
5.2.7.1.3.2. India
5.2.7.1.3.3. Japan
5.2.7.1.3.4. Australia & New Zealand
5.2.7.1.3.5. South Korea
5.2.7.1.3.6. ASEAN
5.2.7.1.3.7. Rest of Asia Pacific
5.2.7.1.4. Middle East & Africa (MEA)
5.2.7.1.4.1. Saudi Arabia
5.2.7.1.4.2. South Africa
5.2.7.1.4.3. UAE
5.2.7.1.4.4. Rest of MEA
5.2.7.1.5. South America
5.2.7.1.5.1. Argentina
5.2.7.1.5.2. Brazil
5.2.7.1.5.3. Rest of South America

6.1. Market Dynamics and Trends
6.1.1. Growth Drivers
6.1.2. Restraints
6.1.3. Opportunity
6.1.4. Key Trends

6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
6.2.1. Key Insights
6.2.1.1. By Drug Type
6.2.1.2. By Molecule
6.2.1.3. By Indication
6.2.1.4. By Patient Population
6.2.1.5. By Distribution Channel
6.2.1.6. By End User
6.2.1.7. By Country

7.1. Market Dynamics and Trends
7.1.1. Growth Drivers
7.1.2. Restraints
7.1.3. Opportunity
7.1.4. Key Trends

7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
7.2.1. Key Insights
7.2.1.1. By Drug Type
7.2.1.2. By Molecule
7.2.1.3. By Indication
7.2.1.4. By Patient Population
7.2.1.5. By Distribution Channel
7.2.1.6. By End User
7.2.1.7. By Country

8.1. Market Dynamics and Trends
8.1.1. Growth Drivers
8.1.2. Restraints
8.1.3. Opportunity
8.1.4. Key Trends

8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
8.2.1. Key Insights
8.2.1.1. By Drug Type
8.2.1.2. By Molecule
8.2.1.3. By Indication
8.2.1.4. By Patient Population
8.2.1.5. By Distribution Channel
8.2.1.6. By End User
8.2.1.7. By Country

9.1. Market Dynamics and Trends
9.1.1. Growth Drivers
9.1.2. Restraints
9.1.3. Opportunity
9.1.4. Key Trends

9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
9.2.1. Key Insights
9.2.1.1. By Drug Type
9.2.1.2. By Molecule
9.2.1.3. By Indication
9.2.1.4. By Patient Population
9.2.1.5. By Distribution Channel
9.2.1.6. By End User
9.2.1.7. By Country

10.1. Market Dynamics and Trends
10.1.1. Growth Drivers
10.1.2. Restraints
10.1.3. Opportunity
10.1.4. Key Trends

10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
10.2.1. Key Insights
10.2.1.1. By Drug Type
10.2.1.2. By Molecule
10.2.1.3. By Indication
10.2.1.4. By Patient Population
10.2.1.5. By Distribution Channel
10.2.1.6. By End User
10.2.1.7. By Country

11.1. Novo Nordisk
11.2. Eli Lilly
11.3. Pfizer
11.4. Structure Therapeutics
11.5. Viking Therapeutics
11.6. AstraZeneca
11.7. Roche
11.8. Terns Pharmaceuticals
11.9. Jiangsu Hengrui
11.10. Innovent Biologics
11.11. Gan & Lee
11.12. Boehringer Ingelheim
11.13. Zealand Pharma
11.14. OPKO Health / Entera Bio
11.15. Amgen

12.1. List of Secondary Sources
12.2. Key Country Markets- Macro Economic Outlook/Indicators